Reading this on a mobile device? Try our optimized mobile version here:

March 20, 2013
Are you part of a BD or licensing team and want to improve your skills in contracts, intellectual property, valuation and deal structuring? Register for BIO's Executive Training Courses, April 9-21, in Chicago.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Takeda licenses 2 drugs to NPS for as much as $80M
    Takeda Pharmaceutical granted NPS Pharmaceuticals complete global rights to develop and market its adult short bowel syndrome drug teduglutide and recombinant human parathyroid hormone 1-84, which is approved in Europe for post-menopausal osteoporosis. The deal covers all assets related to the two products. NPS will pay Takeda $50 million in common stock and a potential $30 million milestone fee. Genetic Engineering & Biotechnology News (3/19) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • Amgen's skin cancer drug hits main goal in late-stage trial
    Sixteen percent of patients who took Amgen's experimental advanced melanoma drug talimogene laherparepvec experienced at least partial tumor shrinkage for six months, compared with 2% of patients who received subcutaneous granulocyte-macrophage colony-stimulating factor, preliminary data from a late-stage trial showed. A detailed look at the study is set for release at a medical meeting this year. Reuters (3/19) LinkedInFacebookTwitterEmail this Story
  • Justices hear arguments about generic-drug liability
    The Supreme Court heard arguments on Tuesday about whether generic-drug makers can be held liable under state law for alleged flaws in the designs of drugs. Justice Antonin Scalia said that if state law takes precedence, it could take complex decisions out of the hands of the FDA and instead juries would have to consider "what the cost-benefit analysis is for a very novel drug that unquestionably has some deleterious effects, but also can save some lives." A decision is anticipated by the end of June. Reuters (3/19), The Wall Street Journal (3/19), The New York Times (tiered subscription model) (3/19) LinkedInFacebookTwitterEmail this Story
  • Drugmakers cut antibiotics R&D as superbugs take hold
    Despite concerns about drug-resistant bacteria, few drugmakers are developing new antibiotics and some have trimmed their antibiotics research spending. Regulatory hurdles and relatively low market pricing make antibiotics development unattractive. Public-private partnerships might shift the playing field, and more research sharing could boost innovation, GlaxoSmithKline CEO Andrew Witty said. Reuters (3/18) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
  • Firms, CIGENE team up to identify salmon biomarker patterns
    Aqua Gen, Affymetrix and the Center for Integrative Genomics are developing a genetic screening array for the study of salmon. They have identified 923,627 markers, as well as diploid and tetraploid sequence variants for use in genomics and ecology studies. "This high-density SNP array gives us entirely new possibilities for improving the disease resistance and robustness of farmed Atlantic salmon," Aqua Gen R&D director Nina Santi said. GenomeWeb Daily News (free registration) (3/19) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Chemtex looks at N.C. for new biofuel refinery
    Chemtex hopes to build a biofuel refinery in Sampson County, N.C., and open it in 2015, according to the company. "I'm very confident that in 2015, this plant will be open somewhere, and I should say we're still very hopeful and it's our intention to open in North Carolina. It's really making sure it's a project that's welcome in the state," said Dennis Leong, executive vice president of marketing and business development at Chemtex. The Fayetteville Observer (N.C.) (3/18) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Quality is not an act, it is a habit."
Greek philosopher

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information